<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694924</url>
  </required_header>
  <id_info>
    <org_study_id>S63359</org_study_id>
    <nct_id>NCT04694924</nct_id>
  </id_info>
  <brief_title>Prospective Prostate Cancer and Patient-reported Outcomes Registry</brief_title>
  <acronym>Prosquare</acronym>
  <official_title>Promoting Quality of Care: a Prospective Cohort Study of Localized and Locally Advanced Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital Groeninge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Blasius Dendermonde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the use of a digital solution, integrated into the electronic&#xD;
      health record, for prospective and structured reporting of clinical and patient-reported&#xD;
      outcomes for patients diagnosed with localized or locally advanced prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Assessment of systematically reporting a standardized set of predefined clinical parameters</measure>
    <time_frame>up to 10 years after diagnosis</time_frame>
    <description>The proportion of patients who are enrolled in the registry over the total localized and locally advanced prostate cancer patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of systematically collecting a predefined set of patient-reported outcomes</measure>
    <time_frame>up to 10 years after diagnosis</time_frame>
    <description>The proportion of patients who completed all questionnaires over the total of questionnaires send.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of disease recurrence/progression</measure>
    <time_frame>up to 10 years after diagnosis</time_frame>
    <description>Biochemical prostate specific antigen (PSA) recurrence/progression and recurrence/progression based on medical imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life</measure>
    <time_frame>at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis</time_frame>
    <description>Assessment of health-related quality of life in prostate cancer patients. Measured by EORTC QLQ-C30. The EORTC QLQ-C30 is a generic QoL questionnaire designed to cover issues important to all cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific quality of life</measure>
    <time_frame>at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis</time_frame>
    <description>Measured by EPIC26. EPIC-26 is a validated instrument that measures the quality of life across 5 disease-specific domains: urinary incontinence, urinary obstruction and irritation, bowel-related symptoms, sexual dysfunction, and hormonal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 10 years after diagnosis</time_frame>
    <description>Overall survival is defined as the time from enrollment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Cancer (PC)-related Mortality (PM)</measure>
    <time_frame>up to 10 years after diagnosis</time_frame>
    <description>PC-related mortality is the death due to prostate cancer.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Locally Advanced Prostate Carcinoma</condition>
  <condition>Locally Advanced Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Localized and locally advanced prostate cancer</arm_group_label>
    <description>Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.&#xD;
Clinical outcomes will be reported via predefined electronic forms, integrated into the EHR. Patient-reported outcomes will be collected electronically.&#xD;
All treatment decisions will be made at the discretion of the investigator or treating physician.</description>
    <arm_group_label>Localized and locally advanced prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with newly diagnosed histologically proven localized and locally advanced&#xD;
        prostate cancer referred to one of the participating sites will be eligible to be enrolled&#xD;
        in the cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathology confirmed diagnosis of localized or locally advanced prostate cancer&#xD;
&#xD;
          -  Being able to speak, read and understand Dutch, French, or English&#xD;
&#xD;
          -  Each patient (or their legally acceptable representative) must sign an informed&#xD;
             consent form (ICF) indicating that he understands the purpose of, and is willing to&#xD;
             participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior treatment for prostate malignancies will be excluded.&#xD;
&#xD;
          -  Dementia, mental alteration, or psychiatric pathology that can compromise informed&#xD;
             consent from the patient and/ or adherence to the protocol and the monitoring of the&#xD;
             trial&#xD;
&#xD;
          -  Patients who cannot submit themselves to following the protocol for psychological&#xD;
             reasons, social, family, or geographical.&#xD;
&#xD;
          -  Persons deprived of liberty or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wouter Everaerts, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven / KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wouter Everaerts, MD, PhD</last_name>
    <phone>+3216346687</phone>
    <email>wouter.everaerts@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <state>Oost-Vlaanderen</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Ost, MD, PhD</last_name>
      <phone>052 25 25 05</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Everaerts, MD, PhD</last_name>
      <phone>016346687</phone>
      <email>wouter.everaerts@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Andries Clinckaert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Uvin, MD, PhD</last_name>
      <phone>050 45 25 30</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <state>West-Vlaanderen</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siska Van Bruwaene, MD, PhD</last_name>
      <phone>056 63 38 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

